LPCN
LPCN
NASDAQ · Pharmaceuticals

Lipocine Inc

$1.61
+0.08 (+5.23%)
As of Nov 7, 2:38 AM ET ·
Financial Highlights (FY 2026)
Revenue
2.84M
Net Income
-13,842,956
Gross Margin
—
Profit Margin
-487.1%
Rev Growth
+58.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 28.1% 28.1%
Operating Margin -524.7% -472.2% 13.6% 14.9%
Profit Margin -487.1% -462.7% 16.1% 15.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 2.84M 1.80M 22.16M 17.20M
Gross Profit — — 6.23M 4.83M
Operating Income -14,913,751 -8,488,727 3.02M 2.56M
Net Income -13,842,956 -7,879,243 3.56M 2.74M
Gross Margin — — 28.1% 28.1%
Operating Margin -524.7% -472.2% 13.6% 14.9%
Profit Margin -487.1% -462.7% 16.1% 15.9%
Rev Growth +58.1% +58.1% +9.7% +22.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 4.92M 5.58M
Total Equity — — 36.70M 40.60M
D/E Ratio — — 0.13 0.14
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -14,824,632 -8,906,779 4.85M 3.77M
Free Cash Flow — — 3.49M 2.02M